Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938791 | 1.00 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL938782 | 1.00 | MEN1 (0.51) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL1764829 | 0.98 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL8153240 | 0.98 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL8541058 | 0.98 | MEN1 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL169110 | 0.94 | CHRNB2 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL6179150 | 0.94 | CHRNB2 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL169111 | 0.94 | CHRNB2 (0.50) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL3335329 | 0.92 | CHRNB2 (0.49) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL3335334 | 0.92 | CHRNB2 (0.49) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4588920-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-07-23 | — | — | EP | disclosed |
| CN-119968371-A | Novel PRMT5 inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024067445-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-117802177-A | Method for synthesizing single chiral 2-aryl substituted nitrogen heterocyclic derivative by imine reductase catalysis and application thereof | 南京药石科技股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-108290881-B | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2008006703-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878721-A1 | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | NOVO NORDISK A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| CN-1087083-A | The intermediates preparation of synthetic 3-amino piperidine derivatives | PFIZER (US) | 1994-05-25 | — | — | CN | disclosed |
| CN-1053060-A | 3-aminopiperidine derivatives and related nitrogen-containing heterocycles | PFIZER (US) | 1991-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | MEN1 1085/4885CYP2D6 3157/4885CYP2C19 3902/4885 |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | MEN1 1776/4885CYP2D6 2211/4885CYP2C19 1938/4885 |
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | MEN1 463/4885CYP2D6 1719/4885CYP2C19 1074/4885 |
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HSD11B1, HSD3B1, HSD17B1 | MEN1 2800/4885CYP2D6 365/4885CYP2C19 390/4885 |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | MEN1 463/4885CYP2D6 1719/4885CYP2C19 1074/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | MEN1 463/4885CYP2D6 1719/4885CYP2C19 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.